Another case of a pancreatic cancer patient with a 6174delT BRCA2 mutation showed prolonged survival after docetaxel, capecitabine, and gemcitibine combination followed by single agent irinotecan, despite prognostically unfavorable disease [50]. The gene discussed is BRCA2; the disease is pancreatic neoplasm.